ATE446372T1 - Vesikuläre komplexe und verfahren zu deren herstellung und verwendung - Google Patents

Vesikuläre komplexe und verfahren zu deren herstellung und verwendung

Info

Publication number
ATE446372T1
ATE446372T1 AT98920077T AT98920077T ATE446372T1 AT E446372 T1 ATE446372 T1 AT E446372T1 AT 98920077 T AT98920077 T AT 98920077T AT 98920077 T AT98920077 T AT 98920077T AT E446372 T1 ATE446372 T1 AT E446372T1
Authority
AT
Austria
Prior art keywords
disclosed
individuals
methods
production
cells
Prior art date
Application number
AT98920077T
Other languages
English (en)
Inventor
Richard Ciccarelli
C Satishchandran
Catherine Pachuk
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE446372T1 publication Critical patent/ATE446372T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98920077T 1997-04-30 1998-04-30 Vesikuläre komplexe und verfahren zu deren herstellung und verwendung ATE446372T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4512297P 1997-04-30 1997-04-30
PCT/US1998/008799 WO1998048780A1 (en) 1997-04-30 1998-04-30 Vesicular complexes and methods of making and using the same

Publications (1)

Publication Number Publication Date
ATE446372T1 true ATE446372T1 (de) 2009-11-15

Family

ID=21936112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98920077T ATE446372T1 (de) 1997-04-30 1998-04-30 Vesikuläre komplexe und verfahren zu deren herstellung und verwendung

Country Status (12)

Country Link
US (2) US6217900B1 (de)
EP (1) EP0986372B1 (de)
JP (1) JP2002508747A (de)
KR (1) KR100554344B1 (de)
CN (1) CN1092045C (de)
AT (1) ATE446372T1 (de)
AU (1) AU728115C (de)
BR (1) BR9809006B1 (de)
CA (1) CA2285298C (de)
DE (1) DE69841251D1 (de)
ES (1) ES2333282T3 (de)
WO (1) WO1998048780A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061032A1 (en) * 1998-05-25 1999-12-02 Nippon Shinyaku Co., Ltd. Process for producing composite preparation containing nucleic acid
EP2314700A1 (de) * 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Zusammensetzung und Verfahren zur in vivo und in vitro Abschwächung der Genexpression mittels dobbelsträngiger RNA
EP1097993A3 (de) * 1999-11-05 2004-01-07 National Institute of Advanced Industrial Science and Technology Funktionelle Ribozymchimermolekulen die schlittfähig sind
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7461046B2 (en) * 2002-02-07 2008-12-02 The University Of Utah Research Foundation Method for creating and using a treatment protocol
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
WO2003093449A2 (en) * 2002-05-06 2003-11-13 Nucleonics, Inc. Methods for delivery of nucleic acids
JP2005529959A (ja) * 2002-06-14 2005-10-06 マイラス コーポレイション 細胞へのポリヌクレオチドの伝達をするための新規な方法
EP1540004A4 (de) * 2002-07-31 2007-10-03 Nucleonics Inc Doppelstrang-rna-strukturen und -konstrukte sowie verfahren zur erzeugung und verwendung davon
WO2004073631A2 (en) * 2003-02-14 2004-09-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
HUE042261T2 (hu) 2003-06-12 2019-06-28 Alnylam Pharmaceuticals Inc Gén kikapcsolásra alkalmas konzervált HBV és HCV szekvenciák
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
JP2008514202A (ja) 2004-09-24 2008-05-08 ニュークレオニクス・インコーポレイテッド Ｒｎａｉによる一本鎖ウイルスの逆鎖複製中間体のターゲティング
EP2316942B1 (de) 2004-12-22 2021-04-21 Alnylam Pharmaceuticals, Inc. Zum gen-silencing geeignete konservierte hbv- und hcv-sequenzen
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
EP2799547B1 (de) 2006-11-08 2016-12-21 Veritas Bio, LLC In-vivo-Abgabe von RNA an eine Targetzelle
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
EP2365003A1 (de) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC CD37-Immuntherapeutikum und Kombination mit bifunktionellem Chemotherapeutikum davon
JP5883381B2 (ja) 2009-05-05 2016-03-15 ミラゲン セラピューティクス，インコーポレイテッド 親油性ポリヌクレオチド接合体
CA2765129A1 (en) 2009-06-08 2010-12-16 Miragen Therapeutics Chemical modification motifs for mirna inhibitors and mimetics
WO2011121074A1 (en) * 2010-04-01 2011-10-06 Pharmanest Ab Thermogelling anaesthetic compositions
WO2012061810A1 (en) 2010-11-05 2012-05-10 Miragen Therapeutics Base modified oligonucleotides
EA201370139A1 (ru) 2010-12-15 2013-10-30 Мираген Терапеутикс Ингибиторы микро-рнк, содержащие закрытые нуклеотиды
CA2832899A1 (en) 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
EP2755663A4 (de) 2011-09-13 2015-10-07 Ottawa Hospital Res Inst Microrna-inhibitoren
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CA2902571A1 (en) 2013-03-15 2014-09-18 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
EP3068783B1 (de) 2013-11-15 2020-09-23 The Board of Trustees of the Leland Stanford Junior University Agonisten des hypokretin-rezeptors 2 zur verwendung zur behandlung von herzversagen
US10772974B2 (en) 2013-11-18 2020-09-15 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for cardiac regeneration
CN108064175A (zh) 2014-08-04 2018-05-22 米拉根医疗股份有限公司 Myh7b的抑制剂及其用途
AU2015315298B2 (en) 2014-09-08 2020-05-14 MiRagen Therapeutics, Inc. miR-29 mimics and uses thereof
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
MX368314B (es) 2015-06-05 2019-09-27 Miragen Therapeutics Inc Inhibidores del mir-155 para tratar linfoma cutáneo de células t (ctcl).
EP3352760B1 (de) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3-bindende polypeptide
WO2017087486A1 (en) 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
EP3472193A4 (de) 2016-06-20 2020-01-08 The Board of Trustees of the Leland Stanford Junior University Zirkuläre rna und deren verwendung in der immunmodulation
UY37376A (es) 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
ES2659845B1 (es) 2016-09-19 2019-01-04 Univ Valencia Modulación de microRNAs contra la distrofia miotónica tipo 1 y antagonistas de microRNAs para ello
AR113490A1 (es) 2017-12-12 2020-05-06 Amgen Inc CONSTRUCCIONES DE ARNi PARA INHIBIR LA EXPRESIÓN DE PNPLA3 Y MÉTODOS DE USO DE LAS MISMAS
BR112020018705A2 (pt) 2018-03-14 2021-01-05 Beth Israel Deaconess Medical Center Inibidores de microrna 22
CN113166761B (zh) 2018-12-10 2025-09-09 美国安进公司 用于抑制pnpla3表达的rnai构建体
EP3894554A1 (de) 2018-12-10 2021-10-20 Amgen Inc. Chemisch modifizierte rnai-konstrukte und deren verwendung
TW202111124A (zh) 2019-05-30 2021-03-16 美商安進公司 用於抑制ｓｃａｐ表現之ｒｎａｉ構建體及其使用方法
WO2021030613A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
US20230078200A1 (en) 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
WO2021234607A1 (en) 2020-05-20 2021-11-25 St. Jude Children's Research Hospital Detection of alzheimer's disease using specific biomarkers
MX2022015169A (es) 2020-06-01 2023-07-03 Amgen Inc Constructos de arni para inhibir la expresion de hsd17b13 y metodos de uso de los mismos.
EP3929295A1 (de) 2020-06-26 2021-12-29 Universitat Pompeu Fabra Künstliche rnas zur modulation von rna-fragmenten
PE20230993A1 (es) 2020-08-13 2023-06-23 Amgen Inc Construcciones de iarn y metodos para inhibir la expresion de marc1
WO2022098841A1 (en) 2020-11-05 2022-05-12 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
CN118556125A (zh) 2021-10-05 2024-08-27 美国安进公司 用于增强寡核苷酸化合物的基因沉默活性的组合物和方法
CA3235262A1 (en) 2021-10-22 2023-04-27 Amgen Inc. Rnai constructs for inhibiting gpam expression and methods of use thereof
IL317825A (en) 2022-07-25 2025-02-01 Amgen Inc RNA interference constructs and methods for inhibiting fam13a expression
EP4353823A1 (de) 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitoren von mikro-rna 22
AR131389A1 (es) 2022-12-16 2025-03-12 Amgen Inc CONSTRUCTOS DE ARNi PARA INHIBIR LA EXPRESIÓN DE TTR Y MÉTODOS DE USO DE LOS MISMOS
WO2025260042A1 (en) 2024-06-14 2025-12-18 Amgen Inc. Rnai constructs and methods for inhibiting cnr1 expression
WO2026006275A2 (en) 2024-06-26 2026-01-02 Amgen Inc. Rnai constructs and methods for inhibiting expression of inhbe

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5514788A (en) 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU675702B2 (en) * 1993-01-26 1997-02-13 Leslie R. Coney Compositions and methods for delivery of genetic material
DK0800579T3 (da) * 1994-12-30 2002-09-09 Chiron Corp Kombinations-gen-leveringsvehikler
KR20140137679A (ko) 2013-05-23 2014-12-03 삼성전자주식회사 카드 소켓 장치

Also Published As

Publication number Publication date
EP0986372B1 (de) 2009-10-21
DE69841251D1 (de) 2009-12-03
AU728115B2 (en) 2001-01-04
AU728115C (en) 2004-01-22
EP0986372A1 (de) 2000-03-22
CA2285298A1 (en) 1998-11-05
WO1998048780A1 (en) 1998-11-05
CN1277549A (zh) 2000-12-20
AU7272498A (en) 1998-11-24
KR100554344B1 (ko) 2006-02-22
CA2285298C (en) 2008-12-23
US6217900B1 (en) 2001-04-17
CN1092045C (zh) 2002-10-09
ES2333282T3 (es) 2010-02-18
EP0986372A4 (de) 2002-06-19
BR9809006A (pt) 2000-08-08
BR9809006B1 (pt) 2010-02-09
US6383512B1 (en) 2002-05-07
KR20010020161A (ko) 2001-03-15
JP2002508747A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
DE69841251D1 (de) Vesikuläre komplexe und verfahren zu deren herstellung und verwendung
DE69713336D1 (de) Verfahren zur Herstellung von aktivierten markierten tumorspezifischen T-Zellen und deren Verwendung in der Behandlung von Tumoren
DE69837041D1 (de) Verfahren und mikroorganism zur herstellung von purin-nukleosiden durch fermentation
PL319833A1 (en) Compounds and composition for carrying active media
ATE370960T1 (de) Verknüpfte peptid-nukleinsäuren
BR9607273A (pt) Molécula de dna duplo filamento dna recombinante plasmídio célula recombinante composiçao farmacéutica e processo de preparaçao de uma molécula de dna
DE69427144D1 (de) Verfahren und System zur Herstellung von Ethanol aus Mikroalgen
DE69302971D1 (de) Antiperkolation Gasdiffusionselektrode und Verfahren zur deren Herstellung
ATE279441T1 (de) Verfahren zur herstellung von genetisch veränderten lymphozyten vorläuferzellen von wirbeltieren und deren gebrauch zur produktion von heterologen bindeproteinen
SG76092G (en) Manufacture of tetra-alkyl ethenylidene bis phosphonates and use thereof in pharmaceutical compositions
DE69840932D1 (de) Zusammensetzungen und verfahren zur verstärkung der verabreichung von therapeutischen mitteln in zellen
DE69809091D1 (de) Phenylphosphonsäurederivate und deren Herstellung
DE69601613D1 (de) Makromonomere mit hohem Säuregehalt und Verfahren zu deren Herstellung
DE3674559D1 (de) Spiegel in leichtbauweise und verfahren zu seiner herstellung.
FI964582A7 (fi) Aminosulfonihappojohdannaisia, niiden käyttö pseudopeptidisynteesissä ja menetelmä niiden valmistamiseksi
ATE140455T1 (de) Neue 2-amino-5-cyano-1,4-dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
DE59606567D1 (de) Neuer Mikroorganismus, dessen Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren
EP0770137A4 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
DE69318624D1 (de) Aminogruppen-enthaltende Organipolysiloxane und Verfahren zur deren Herstellung
DE3577443D1 (de) Derivate von dihydroorotsaeure, deren verfahren zur herstellung und deren pharmazeutische zusammensetzungen.
DE69611438D1 (de) Bizyclische tachykinin-antagonisten, deren herstellung und deren verwendung in pharmazeutischen zusammmensetzungen
DE69402484D1 (de) Verfahren zur Herstellung von Naphthochinonen sowie Zwischenprodukte bei deren Herstellung
DE69825580D1 (de) Neurotrophischer faktor nnt-1
DE69624953D1 (de) Kosmetika in Stiftform und Verfahren zu deren Herstellung
DE69724454D1 (de) BIS ZU 126K SUPRALEITENDE Ba-Ca-Cu-O-ZUSAMMENSETZUNGEN UND VERFAHREN ZU DEREN HERSTELLUNG

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties